Guardant Health rises after expanding blood test to track cancer therapy response faster

Guardant Health

10/11/2025 14:16

** Shares of medical diagnostics co Guardant Health GH.O rise 2.2% to $98.82 premarket

** Co says it has expanded its "Guardant Reveal blood test" so doctors can track how well treatments are working in patients with advanced solid tumors, without needing a tissue sample

** Test detects tumor signals in blood, flags treatment impact up to 18 months earlier than scans – co says

** Immune therapy study shows test spotted responses five months ahead of imaging, linked to better outcomes - GH

** Co adds single-click ordering across lineup to ease paperwork for doctors

** Up to last close, stock up ~217% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))